Skip to Content

What kind of cancer does Tecentriq treat?

Answers (1)

Official Answer by 1 Jun 2016

Tecentriq (generic name: atezolizumab) treats urothelial cancer, the most common type of bladder cancer causing about 90% of all cases. Also known as a programmed death-ligand 1 (PD-L1) blocking antibody, Roche's Tecentriq was approved on May 18, 2016 and is the first PD-L1 inhibitor approved by the FDA.

Tecentriq is in a new class of immunotherapy drugs called immune checkpoint inhibitors and works by boosting the body’s immune system to help it attack cancer cells. Immune checkpoint inhibitors may also allow the immune system to attack normal organs in the body which may lead to serious side effects, but overall these drugs are better tolerated than many of the older standard cancer treatments.

Common side effects with Tecentriq may include fatigue, loss of appetite, and nausea. Other more serious side effects may include hepatitis, inflammation in the lungs, intestines, or other organs.

Votes: +0 free discount card

Further Information

Search for questions

Still looking for answers? Try searching for what you seek or ask your own question.

Frequently Asked Questions

What are the active ingredients in Qtern?

Posted 5 Jul 2017 1 answerFAQ by

What is the Siliq REMS Program?

Posted 5 Jul 2017 1 answerFAQ by

What type of drug is Emflaza?

Posted 5 Jul 2017 1 answerFAQ by

What is Parsabiv used to treat?

Posted 5 Jul 2017 1 answerFAQ by

Is Xyzal available over-the-counter?

Posted 5 Jul 2017 1 answerFAQ by